临绝经和绝经后妇女减肥GLP-1受体激动剂:当前的证据
Hana Mikdachi1,2, Rebecca Dunsmoor-Su1,3,4,5
1Gennev Medical Group.
Current opinion in obstetrics & gynecology
|February 19, 2025
概括
类似葡萄糖-1受体激动剂 (GLP-1RA) 对女性减肥有效. 需要进行更多的研究,以了解它们对绝经前和绝经后妇女的具体风险和益处.
科学领域:
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
- 妇女健康 妇女健康
背景情况:
- 在更年期前和更年期后的女性中,体重增加很常见.
- 葡萄糖类-1受体激动剂 (GLP-1RA) 越来越多地用于体重管理.
- 有限的数据存在GLP-1RA在这个人口群中的有效性和安全性.
研究的目的:
- 审查关于GLP-1 RA在更年期前和更年期后妇女使用的当前数据.
- 讨论GLP-1RA对该群体体重管理的影响.
主要方法:
- 对临近和绝经后妇女GLP-1RA研究的文献综述.
- 综合了有关疗效和安全性的现有数据.
主要成果:
- GLP-1 RAs在减肥方面表现出一致的有效性.
- 这些药物代表了一种有价值的治疗选择,用于体重管理在前期和绝经后的妇女.
结论:
- GLP-1RA是一种有前途的药理学工具,可以帮助更年期前和更年期后的女性减肥.
- 进一步的研究是必不可少的,以充分阐明GLP-1RA在这个特定人群中的风险,益处和最佳应用.
相关概念视频
Hormonal Regulation
43.1K
Hormones regulate a significant portion of digestion through activation of the neuroendocrine system. The neuroendocrine system of digestion contains many different hormones all with multiple functions that are both, directly and indirectly, involved in digestion.
43.1K
Oral Hypoglycemic Agents: Biguanides and Glitazones
158
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
158
Oral Hypoglycemic Agents: Glinides
131
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
131
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
144
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
144
Glucagon-like Receptor Agonists
291
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
291
Dipeptidyl Peptidase 4 Inhibitors
164
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
164


